All posts
Published
September 11, 2025

Healthcare Investment: A Path to Economic Prosperity in the Global South

Spyeside team analyzes how investing in healthcare and establishing universal access pathways is crucial for accelerating societal and economic growth, especially in resource-constrained environments. Examples from the Global South demonstrate that universal coverage reforms and essential benefits packages not only improve health equity but also accelerate and sustain economic growth long-term.

Spyeside team analyzes how investing in healthcare and establishing universal access pathways is crucial for accelerating societal and economic growth, especially in resource-constrained environments. Examples from the Global South demonstrate that universal coverage reforms and essential benefits packages not only improve health equity but also accelerate and sustain economic growth long-term.

A healthy workforce and population are fundamental to a thriving economy. While the upfront costs of establishing universal healthcare can seem daunting for nations in the Global South, the long-term benefits are undeniable. By improving health outcomes and ensuring access to essential medicines, countries can unlock significant economic potential. This is a strategic investment in human capital that pays dividends in productivity, stability, and sustainable growth.

The Role of Universal Healthcare Schemes & Essential Medicines

Many countries have successfully leveraged policy changes to expand healthcare access. The introduction of Universal Healthcare Schemes (UHS) and National Lists of Essential Medicines (NLEM) are powerful examples. These policies provide a baseline level of care, ensuring that cost-effective medicines are accessible to a wider population. The key to making these initiatives effective lies in linking evidence to policy and medical practice. This is where Health Technology Assessments (HTA) become a game-changer.

Linking Policy to Growth: Key Examples

Thailand is a prime example. Since its establishment in 2007, the HTA body, HITAP, has institutionalized evidence-based practices. By linking health economics to policy, HITAP's recommendations have expanded the NLEM, which serves as the national reimbursement list. This has facilitated coverage for over 95% of Thailand's population under three public health schemes, directly supporting the nation's development goals. (Teerawattananona et.al, 2024)

Vietnam has adopted a similar approach, incorporating HTA outcomes into health insurance decisions since 2014. This strategy has been instrumental in expanding public health services, keeping pace with rapid economic growth and the increasing demands of the labor market. (Lee et.al, 2021).

In Latin America, countries like Brazil (Ortega et.al., 2023) have seen steady gains toward universal coverage through its Unified Health System, even amid fiscal austerity. Colombia (Vergara et.al., 2024) has moved toward a unified, implicitly defined benefits approach. Research in both countries has shown that when benefits policy, payment, and regulation evolve together, access expands, leading to health improvements that accumulate and support human capital formation.

Conclusion

These case studies from Asia and Latin America underscore a critical lesson: universal healthcare and essential benefits are not just social programs; they are vital economic accelerators. By adopting evidence-based frameworks like HTAs, countries in the Global South can make informed decisions that improve health equity and build a stronger, more resilient economy for the future.

Recent News

View All News
Latin America

Mexico's General Circular Economy Law: what comes next on the road to implementation

Speyside Group provides an analytical assessment of Mexico's General Circular Economy Law (LGEC), the framework that introduces Extended Producer Responsibility and circular-design obligations for companies handling plastics, packaging, glass, and paper. With the Regulation due July 19, 2026 and the National Program due in early 2027, this insight maps the pending instruments, the regulatory timeline, and the concrete steps companies should take now to shape their sector obligations
Read post
Public Affairs

How Does Mining Regulation Work in the DRC?

Speyside Group provides an analytical assessment of the complex operating environment in sub-Saharan Africa by unpacking How Does Mining Regulation Work in the DRC. Last revised through major amendments in 2018, the DRC’s regulatory framework, governed by the Mining Code and Mining Regulations, seeks to balance mineral sovereignty with international investments. While the government has made notable efforts to improve compliance by aligning its policies with the Extractive Industries Transparency Initiative (EITI), the operational landscape remains heavily characterized by severe implementation gaps, infrastructure bottlenecks, and institutional capacity constraints. For global mining and energy investors, navigating the country's strategic cobalt, copper, and gold reserves requires a sophisticated approach to rising fiscal demands, strict local ownership requirements, and rapidly shifting geopolitical alliances.
Read post
Latin America

How do I get a product approved through ANVISA in Brazil without it taking five years?

Speyside Group provides a strategic perspective on accelerating market entry within Brazil's healthcare sector by analyzing how to optimize ANVISA Approval Times. A widespread perception among international life sciences firms is that navigating Brazil's national health regulator is a prohibitive, five-year endeavor. However, an operational analysis reveals that this timeline is rarely driven by the statutory framework itself, which mandates legal review deadlines of 120 days for priority cases and 365 days for ordinary ones. Instead, prolonged market access bottlenecks are primarily structural and behavioral, caused by mismatched dossier formatting, a failure to utilize optimized fast-track sub-categories, and falling into successive technical clarification cycles (fila de exigências). To counter these systemic delays, multinational corporations (MNCs) must pivot toward a sophisticated regulatory strategy built on regulatory reliance pathways, early alignment with optimized priority definitions, and precise tracking of ANVISA’s shifting technical parameters.
Read post